Last reviewed · How we verify
Regimen 2, Course 2
At a glance
| Generic name | Regimen 2, Course 2 |
|---|---|
| Sponsor | Baylor College of Medicine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 (PHASE3)
- Safety and Efficacy of OBX-115 in Advanced Solid Tumors (PHASE1, PHASE2)
- Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy (NA)
- Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy (PHASE2)
- Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure (PHASE1)
- Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regimen 2, Course 2 CI brief — competitive landscape report
- Regimen 2, Course 2 updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI